Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 84

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 16
Chunk 84
---

    19,777

    7,111

    Total current liabilities

    85,728

    38,781

    Long-term debt, net of discount

    201,409

    137,842

    Revenue interest financing liability

    333,261

    299,816

    Operating lease liabilities

    —

    462

    Other long-term liabilities

    11,500

    9,700

    Total liabilities

    631,898

    486,601

    Commitments and contingencies (Note 3)

    Stockholders’ deficit:

    Preferred stock, $0.0001 par value; authorized shares — 40,000,000 at December 31, 2024 and December 31, 2023; no shares issued and outstanding at December 31, 2024 and December 31, 2023

    —

    —

    Common stock, $0.0001 par value; authorized shares — 400,000,000 at December 31, 2024 and December 31, 2023; issued and outstanding shares — 68,518,238 and 57,970,044 at December 31, 2024 and December 31, 2023, respectively

    6

    5

    Treasury stock — 19 shares at December 31, 2024 and December 31, 2023

    —

    —

    Additional paid-in capital

    1,009,425

    855,921

    Accumulated deficit

    (1,263,011
    )

    (928,685
    )

    Total stockholders’ deficit

    (253,580
    )

    (72,759
    )

    Total liabilities and stockholders’ deficit
     
    $
    378,318

    $
    413,842

See accompanying notes.

F-4

PHATHOM PHARMACEUTICALS, INC. 

Statements of Operations and Comprehensive Loss 

(in thousands, except share and per share amounts)

    Years EndedDecember 31,

    2024

    2023

    Product revenue, net
     
    $
    55,252

    $
    682

    Cost of revenue

    7,973

    167

    Gross profit

    47,279

    515